Lindis Biotech and Pharmanovia Announce European Marketing Authorization Approval for Catumaxomab, A First-In-Class Treatment for Malignant Ascites
CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER UNDER A LICENSING AGREEM ...
Globe Gazette16h
Capitol Notebook: 2% K-12 funding increase approved by Iowa Senate Republicans
From 1973, when the current public school funding formula was created, until 2010, general state funding to K-12 public schools increased by an annual average of 5%. Since Republicans regained at ...
Targeted Oncology16h
Mushtaq Examines Long-Term Toxicities of CAR T-Cell Therapy in Multiple Myeloma
During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...
GlobalData on MSN23h
Lineage begins study of OPC1 delivering device for spinal cord injury treatment
An allogeneic stem cell-derived transplant, OPC1 helps restore or increase the functional activity in SCI patients. It is tailored to replace the spinal cord cells that are either ...
Science Daily8h
AI unlocks genetic clues to personalize cancer treatment
A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...